NMOSD
MCID: NRM008
MIFTS: 33

Neuromyelitis Optica Spectrum Disorder (NMOSD)

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Neuromyelitis Optica Spectrum Disorder

MalaCards integrated aliases for Neuromyelitis Optica Spectrum Disorder:

Name: Neuromyelitis Optica Spectrum Disorder 53
Neuromyelitis Optica 73
Nmosd 53

Classifications:



External Ids:

UMLS 73 C0027873

Summaries for Neuromyelitis Optica Spectrum Disorder

MalaCards based summary : Neuromyelitis Optica Spectrum Disorder, also known as neuromyelitis optica, is related to neuromyelitis optica and multiple sclerosis. An important gene associated with Neuromyelitis Optica Spectrum Disorder is AQP4 (Aquaporin 4). The drugs Prednisone and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and b cells.

Related Diseases for Neuromyelitis Optica Spectrum Disorder

Diseases in the Neuromyelitis Optica family:

Neuromyelitis Optica Spectrum Disorder

Diseases related to Neuromyelitis Optica Spectrum Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 89)
# Related Disease Score Top Affiliating Genes
1 neuromyelitis optica 11.4
2 multiple sclerosis 10.9
3 myelitis 10.7
4 optic neuritis 10.7
5 neuritis 10.7
6 sjogren syndrome 10.6
7 transverse myelitis 10.6
8 encephalitis 10.4
9 depression 10.4
10 autoimmune disease 10.4
11 systemic lupus erythematosus 10.4
12 myasthenia gravis 10.4
13 autoimmune disease 1 10.4
14 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.4
15 lupus erythematosus 10.4
16 myasthenia gravis congenital 10.4
17 anxiety 10.3
18 scleroderma, familial progressive 10.2
19 hepatitis 10.2
20 hepatitis b 10.2
21 lymphoma 10.2
22 apraxia 10.2
23 adenocarcinoma 10.2
24 internuclear ophthalmoplegia 10.2
25 viral infectious disease 10.2
26 encephalopathy 10.2
27 spondyloarthropathy 1 10.1
28 spinocerebellar ataxia 31 10.1
29 esophageal cancer 10.1
30 split-hand/foot malformation 1 10.1
31 anemia, autoimmune hemolytic 10.1
32 galactorrhea 10.1
33 biotinidase deficiency 10.1
34 ataxia and polyneuropathy, adult-onset 10.1
35 lung cancer susceptibility 3 10.1
36 dengue virus 10.1
37 membranous nephropathy 10.1
38 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.1
39 arteriovenous fistula 10.1
40 b-cell lymphomas 10.1
41 brain injury 10.1
42 bronchiolitis obliterans 10.1
43 follicular lymphoma 10.1
44 hemolytic anemia 10.1
45 restless legs syndrome 10.1
46 aphasia 10.1
47 postural orthostatic tachycardia syndrome 10.1
48 dermatomyositis 10.1
49 parotitis 10.1
50 meningoencephalitis 10.1

Graphical network of the top 20 diseases related to Neuromyelitis Optica Spectrum Disorder:



Diseases related to Neuromyelitis Optica Spectrum Disorder

Symptoms & Phenotypes for Neuromyelitis Optica Spectrum Disorder

Drugs & Therapeutics for Neuromyelitis Optica Spectrum Disorder

Drugs for Neuromyelitis Optica Spectrum Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 90)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Mycophenolic acid Approved Phase 4 24280-93-1 446541
3
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
4 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1,Phase 2
5 Hormones Phase 4,Phase 3,Phase 1,Phase 2
6 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
7 Antibiotics, Antitubercular Phase 4
8 Anti-Bacterial Agents Phase 4
9 Anti-Infective Agents Phase 4
10 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2
11 glucocorticoids Phase 4,Phase 3,Phase 1,Phase 2
12 Antitubercular Agents Phase 4
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
14 Topoisomerase Inhibitors Phase 4
15 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
16 Analgesics Phase 4
17
Prednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 50-24-8 5755
18
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 1,Phase 2 302-25-0
19
Methylprednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 83-43-2 6741
20
Methylprednisolone hemisuccinate Approved Phase 3,Phase 1,Phase 2 2921-57-5
21
Azathioprine Approved Phase 2, Phase 3,Phase 3 446-86-6 2265
22
rituximab Approved Phase 2, Phase 3,Phase 1 174722-31-7 10201696
23
Prednisolone hemisuccinate Experimental Phase 3,Phase 1,Phase 2 2920-86-7
24 Methylprednisolone acetate Phase 3,Phase 1,Phase 2
25 Protective Agents Phase 3,Phase 1,Phase 2
26 Prednisolone acetate Phase 3,Phase 1,Phase 2
27 Gastrointestinal Agents Phase 3,Phase 1,Phase 2
28 Autonomic Agents Phase 3,Phase 1,Phase 2
29 Antiemetics Phase 3,Phase 1,Phase 2
30 Neuroprotective Agents Phase 3,Phase 1,Phase 2
31 Immunologic Factors Phase 2, Phase 3,Phase 3,Phase 1
32 Antibodies Phase 3,Phase 2,Phase 1,Not Applicable
33 Immunoglobulins Phase 3,Phase 2,Phase 1,Not Applicable
34 Immunosuppressive Agents Phase 2, Phase 3,Phase 3,Phase 1
35 Antirheumatic Agents Phase 2, Phase 3,Phase 3,Phase 1
36 Antimetabolites Phase 2, Phase 3,Phase 3
37 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 3
38 gamma-Globulins Phase 3,Phase 2
39 Immunoglobulins, Intravenous Phase 3,Phase 2
40 Rho(D) Immune Globulin Phase 3,Phase 2
41 Immunoglobulin G Phase 3
42 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1
43
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
44
Cetirizine Approved Phase 1, Phase 2 83881-51-0 2678
45
Histamine Approved, Investigational Phase 1, Phase 2 51-45-6, 75614-87-8 774
46
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
47
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
48
Metoclopramide Approved, Investigational Phase 2 364-62-5 4168
49
4-Aminopyridine Approved Phase 2 504-24-5 1727
50
Cyclophosphamide Approved, Investigational Phase 1, Phase 2,Phase 2 6055-19-2, 50-18-0 2907

Interventional clinical trials:

(show all 49)
# Name Status NCT ID Phase Drugs
1 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Unknown status NCT02809079 Phase 4 Mycophenolate mofetil;Prednisone
2 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4 Mitoxantrone
3 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
4 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
5 Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients Completed NCT03002038 Phase 2, Phase 3 Azathioprine;Rituximab
6 A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) Completed NCT01892345 Phase 3 Eculizumab
7 A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders Recruiting NCT03330418 Phase 3
8 Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders Active, not recruiting NCT03350633 Phase 2, Phase 3 Tocilizumab Injection;Azathioprine
9 A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Active, not recruiting NCT02200770 Phase 2, Phase 3
10 An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients Active, not recruiting NCT02003144 Phase 3
11 Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD Active, not recruiting NCT02028884 Phase 3 satralizumab (SA237);Placebo
12 Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD Active, not recruiting NCT02073279 Phase 3 satralizumab (SA237);Placebo
13 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Terminated NCT02398994 Phase 3 Intravenous Methylprednisolone;Intravenous Immunoglobulin
14 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
15 Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. Completed NCT01845584 Phase 2 NPB-01
16 Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder Completed NCT02893111 Phase 2 Bortezomib
17 Neuromyelitis Optica (NMO) & Cetirizine Completed NCT02865018 Phase 1, Phase 2 cetirizine
18 Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders Completed NCT02249676 Phase 2
19 An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica Completed NCT00904826 Phase 1, Phase 2 Eculizumab
20 A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD Completed NCT03062579 Phase 1, Phase 2 Tocilizumab
21 Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Completed NCT02166346 Phase 2 Dalfampridine;Placebo
22 Hematopoietic Stem Cell Transplant in Devic's Disease Active, not recruiting NCT00787722 Phase 1, Phase 2 Cyclophosphamide;G-CSF;rATG;Mesna;Rituximab;Methylprednisolone
23 Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica Terminated NCT01339455 Phase 1, Phase 2
24 Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses Unknown status NCT02087813 Phase 1 Alpha1-antitrypsin;methylprednisolone
25 C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation Completed NCT01759602 Phase 1 C1-esterase inhibitor (Cinryze)
26 Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations Completed NCT01777412 Phase 1 Bevacizumab
27 Safety and Tolerability of Rituximab in Neuromyelitis Optica Completed NCT00501748 Phase 1 Rituximab
28 Central Pain Study for ABX-1431 Completed NCT03138421 Phase 1 ABX-1431 HCl;Placebo
29 Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B Recruiting NCT02283671 Phase 1
30 Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Active, not recruiting NCT02276963 Phase 1 Ublituximab
31 Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20 Not yet recruiting NCT03605238 Phase 1
32 Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct Unknown status NCT01024985
33 The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset Unknown status NCT02886377
34 Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis Completed NCT03122873
35 Pathologic-MRI Findings in Atypical IIDD Completed NCT03121105
36 Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders Recruiting NCT02836327
37 Pediatric NMOSD Observational Study Recruiting NCT03766347
38 The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS) Recruiting NCT02850705
39 The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders Recruiting NCT01623076
40 The French Multiple Sclerosis Registry Recruiting NCT02889965
41 Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients Recruiting NCT02789670
42 Stem Cell Ophthalmology Treatment Study II Recruiting NCT03011541 Not Applicable
43 Maintenance Plasma Exchange for Neuromyelitis Optica Active, not recruiting NCT01500681
44 Scrambler Trial for Pain in NMOSD Active, not recruiting NCT03452176 Not Applicable
45 Biobank For MS And Other Demyelinating Diseases Active, not recruiting NCT00445367
46 Optical Coherence Tomography and Optic Neuritis (OCTON) Active, not recruiting NCT02573792
47 Clinic Registry Study of Optic Neuromyelitis Spectrum Disease in China Enrolling by invitation NCT03514030
48 Stem Cell Ophthalmology Treatment Study Enrolling by invitation NCT01920867 Not Applicable
49 Optic Neuritis Differential Diagnosis Study Not yet recruiting NCT03370965 Not Applicable

Search NIH Clinical Center for Neuromyelitis Optica Spectrum Disorder

Genetic Tests for Neuromyelitis Optica Spectrum Disorder

Anatomical Context for Neuromyelitis Optica Spectrum Disorder

MalaCards organs/tissues related to Neuromyelitis Optica Spectrum Disorder:

41
Brain, Spinal Cord, B Cells, T Cells, Eye, Bone, Lung

Publications for Neuromyelitis Optica Spectrum Disorder

Articles related to Neuromyelitis Optica Spectrum Disorder:

(show top 50) (show all 833)
# Title Authors Year
1
Association of GTF2IRD1-GTF2I polymorphisms with neuromyelitis optica spectrum disorders in Han Chinese patients. ( 30531019 )
2019
2
A Case of Transient Pulmonary Interstitial Lesions in Aquaporin-4-positive Neuromyelitis Optica Spectrum Disorder. ( 29780127 )
2018
3
Mycobacterium avium subspecies paratuberculosis and myelin basic protein specific epitopes are highly recognized by sera from patients with Neuromyelitis optica spectrum disorder. ( 29519720 )
2018
4
Eye movement abnormalities in AQP4-IgG positive neuromyelitis optica spectrum disorder. ( 29249386 )
2018
5
Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis. ( 29414288 )
2018
6
Neuromyelitis optica spectrum disorder presenting as rhomboencephalitis. ( 29794010 )
2018
7
Neuromyelitis optica spectrum disorder mimicking extensive leukodystrophy. ( 29676204 )
2018
8
Spectrum of MRI brain lesion patterns in neuromyelitis optica spectrum disorder: a pictorial review. ( 29388807 )
2018
9
Ovarian Reserve in Women With Neuromyelitis Optica Spectrum Disorder. ( 29973905 )
2018
10
Cerebrospinal fluid mitochondrial DNA in neuromyelitis optica spectrum disorder. ( 29703264 )
2018
11
B cell depleting therapy for multiple sclerosis overlapping with neuromyelitis optica spectrum disorder. ( 29621743 )
2018
12
Bortezomib for Neuromyelitis Optica Spectrum Disorder: A New Therapeutic Option for the More Severe Forms? ( 29159373 )
2018
13
The IL-10-producing regulatory B cells (B10 cells) and regulatory T cell subsets in neuromyelitis optica spectrum disorder. ( 29349658 )
2018
14
Corrigendum to "Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder" [Journal of Neuroimmunology 317C (2018) pp. 1-4]. ( 29606296 )
2018
15
Epidemiology of neuromyelitis optica spectrum disorder. ( 29732539 )
2018
16
Immunoadsorption plasmapheresis treatment for the recurrent exacerbation of neuromyelitis optica spectrum disorder with a fluctuating anti-aquaporin-4 antibody level. ( 29675599 )
2018
17
Mutation of the cellular adhesion molecule NECL2 is associated with neuromyelitis optica spectrum disorder. ( 29627007 )
2018
18
Association of Visual Impairment in Neuromyelitis Optica Spectrum Disorder With Visual Network Reorganization. ( 29297041 )
2018
19
Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder. ( 29695599 )
2018
20
Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder: Do They Share Common Targets? ( 29073350 )
2018
21
Bortezomib for Neuromyelitis Optica Spectrum Disorder: A New Therapeutic Option for the More Severe Forms? ( 29159372 )
2018
22
Neuromyelitis Optica Spectrum Disorder Presenting with Pseudoathetosis. ( 29629549 )
2018
23
Incidence of neuromyelitis optica spectrum disorder in the Central Denmark Region. ( 29359475 )
2018
24
MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder. ( 29670575 )
2018
25
Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment. ( 29929977 )
2018
26
Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder. ( 29783157 )
2018
27
Validation of the Modified Fatigue Impact Scale and the relationships among fatigue, pain and serum interleukin-6 levels in patients with neuromyelitis optica spectrum disorder. ( 29406915 )
2018
28
Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. ( 29406904 )
2018
29
Development of Neuromyelitis Optica Spectrum Disorder and Spinal Arachnoid Cysts in a Patient With Intractable Epilepsy. ( 29379967 )
2018
30
Bortezomib for Neuromyelitis Optica Spectrum Disorder: A New Therapeutic Option for the More Severe Forms?-Reply. ( 29159366 )
2018
31
Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report. ( 29361915 )
2018
32
Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder. ( 29414297 )
2018
33
Study of the placentae of patients with neuromyelitis optica spectrum disorder. ( 29571847 )
2018
34
Use of Rituximab and Risk of Re-hospitalization for Children with Neuromyelitis Optica Spectrum Disorder. ( 29782625 )
2018
35
Comparative study of quality of life, anxiety, depression, and fatigue among patients with neuromyelitis optica spectrum disorder and multiple sclerosis: The first report from Iran. ( 29775851 )
2018
36
Resilience and depression/anxiety symptoms in multiple sclerosis and neuromyelitis optica spectrum disorder. ( 30176401 )
2018
37
Diagonistic Apraxia: A Unique Case of Corpus Callosal Disconnection Syndrome and Neuromyelitis Optica Spectrum Disorder. ( 30147671 )
2018
38
Neuromyelitis optica spectrum disorder associated with dengue virus infection. ( 29475624 )
2018
39
Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Neuromyelitis Optica in Singapore. ( 30315559 )
2018
40
Neuromyelitis Optica and Herpes Simplex Virus 2: A Viral Trigger for Aquaporin-4 Autoimmunity? ( 29722742 )
2018
41
Severe aquaporin 4-IgG-positive neuromyelitis optica with disseminated herpes zoster in a pregnant woman successfully treated with intravenous immunoglobulin. ( 29552355 )
2018
42
Hypersomnia as an isolated symptom of neuromyelitis optica. ( 30517996 )
2018
43
Anti-Mycobacterial Antibodies in Paired Cerebrospinal Fluid and Serum Samples from Japanese Patients with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder. ( 30544526 )
2018
44
Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. ( 30377816 )
2018
45
Quantitative radiomic biomarkers for discrimination between neuromyelitis optica spectrum disorder and multiple sclerosis. ( 30408268 )
2018
46
Recurrent optic neuritis - Different patterns in multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody disease. ( 30267996 )
2018
47
Specificity of Lower Urinary Tract Symptoms in Neuromyelitis Optica in Comparison With Multiple Sclerosis Patients. ( 30286581 )
2018
48
Distinct patterns of glia repair and remyelination in antibody-mediated demyelination models of multiple sclerosis and neuromyelitis optica. ( 30240044 )
2018
49
Multiple sclerosis and neuromyelitis optica spectrum disorders in Malaysia: A comparison in different ethnic groups. ( 30172173 )
2018
50
High levels of antibodies against PtpA and PknG secreted by Mycobacterium avium ssp. paratuberculosis are present in neuromyelitis optica spectrum disorder and multiple sclerosis patients. ( 30196833 )
2018

Variations for Neuromyelitis Optica Spectrum Disorder

Expression for Neuromyelitis Optica Spectrum Disorder

Search GEO for disease gene expression data for Neuromyelitis Optica Spectrum Disorder.

Pathways for Neuromyelitis Optica Spectrum Disorder

GO Terms for Neuromyelitis Optica Spectrum Disorder

Sources for Neuromyelitis Optica Spectrum Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....